Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Array Biopharma Inc. (NasdaqNM:ARRY)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug  7Conference call: Array BioPharma Earnings (Q4 2001)
Aug  6Earnings Announcement
Location
1885 33rd Street
Boulder, CO 80301
Phone: (303) 381-6600
Fax: (303) 449-5376
Employees (last reported count): 120
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 57%
·Institutional: 25% (57% of float)
(54 institutions)
·Net Inst. Buying: 792.0K shares (+12.14%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Array BioPharma, Inc. (Array) is a discovery research company creating drug candidates through innovations in chemistry. The Company's experienced scientists provide products and services to create, evaluate and optimize potential drug candidates in collaboration with pharmaceutical and biotechnology companies. Array believes its information-based approach improves the efficiency of the drug discovery process and increases the quality of potential drug candidates. The Company also applies these capabilities internally for its own drug discovery programs. Array provides a broad range of drug discovery products and services, including: optimer building blocks; lead generation; lead optimization; and process research and development. The Company offers products and services to collaborators across the drug discovery process. The Company's proprietary chemoinformatics platform supports the entire drug discovery process.
More from Market Guide: Expanded Business Description

Financial Summary
Array BioPharma is a discovery research company creating drug candidates through innovations in chemistry by providing products and services in collaboration with pharmaceutical companies. For the nine months ended 3/31/01, revenues totalled $11.3 million, up from $4.5 million. Net loss applicable to Common totalled $14 million, up from $3.3 million. Results reflect increased sales of the Company's lead optimization services, offset by increased staffing levels.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 5,671; after tax earnings were -1,381. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

Kyle Lefkoff, 41
Chairman
--  --  
Robert Conway, 46
CEO, Director
$280K--  
Kevin Koch, Ph.D, 40
Pres, Director and CSO
160K$78K
Michael Carruthers, 42
CFO, Sec.
112K370K
David Snitman, Ph.D, 48
COO, VP-Bus. Devel., Director
160K--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ARRYAs of 31-Aug-2001
Price and Volume
52-Week Low
on 26-Mar-2001
$4.172
Recent Price$10.40 
52-Week High
on 30-Nov-2000
$13.00 
Daily Volume (3-month avg)133.3K
Daily Volume (10-day avg)130.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change+57.0%
26-Week Change
relative to S&P500
+70.9%
Share-Related Items
Market Capitalization$240.7M
Shares Outstanding23.1M
Float10.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$2.73 
Earnings (ttm)-$2.65 
Earnings (mrq)-$0.07 
Sales (ttm)$1.15 
Cash (mrq*)$2.43 
Valuation Ratios
Price/Book (mrq*)3.81 
Price/EarningsN/A 
Price/Sales (ttm)9.07 
Income Statements
Sales (ttm)$17.0M
EBITDA (ttm*)-$9.53M
Income available to common (ttm)-$15.4M
Profitability
Profit Margin (ttm)-61.1%
Operating Margin (ttm)-86.3%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-21.88%
Return on Equity (ttm)-41.53%
Financial Strength
Current Ratio (mrq*)6.91 
Debt/Equity (mrq*)0.08 
Total Cash (mrq)$47.7M
Short Interest
As of 8-Aug-2001
Shares Short56.0K
Percent of Float0.6%
Shares Short
(Prior Month)
94.0K
Short Ratio0.34 
Daily Volume165.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.